

In the Claims

1 (currently amended). An isolated polypeptide that:

- (i) comprises or consists of the amino acid sequence as recited in SEQ ID NO:2;
- (ii) is a fragment of SEQ ID NO:2; or
- (iii) has greater than 90%-than 95% sequence identity with the polypeptide of SEQ ID NO: 2 or a fragment thereof;

wherein said isolated polypeptide or fragment has anti-viral activity, antiproliferative activity on cancer cells, the ability to increase levels of TNF- $\alpha$ , IL-2, IL-4, IFN- $\gamma$ , aspartate aminotransferase (ASAT) or alanine aminotransferase (ALAT) *in vivo*, or the ability to induce IFN- $\gamma$  secretion by concanavalin A or phytohemagglutinin stimulated peripheral blood mononuclear cells.

2-5 (canceled).

6 (currently amended). The isolated polypeptide according claim 1, wherein said polypeptide has greater than 95% sequence identity with the polypeptide of SEQ ID NO: 2 or a fragment thereof and has anti-viral activity, antiproliferative activity on cancer cells, the ability to increase levels of TNF- $\alpha$ , IL-2, IL-4, IFN- $\gamma$ , aspartate aminotransferase (ASAT) or alanine aminotransferase (ALAT) *in vivo*, or the ability to induce IFN- $\gamma$  secretion by concanavalin A or phytohemagglutinin stimulated peripheral blood mononuclear cells .

7 (currently amended). The isolated polypeptide according claim 1, wherein said polypeptide has greater than 98% sequence identity with the polypeptide of SEQ ID NO: 2 or a fragment thereof and has anti-viral activity, antiproliferative activity on cancer cells, the ability to increase levels of TNF- $\alpha$ , IL-2, IL-4, IFN- $\gamma$ , aspartate aminotransferase (ASAT) or alanine aminotransferase (ALAT) *in vivo*, or the ability to induce IFN- $\gamma$  secretion by concanavalin A or phytohemagglutinin stimulated peripheral blood mononuclear cells.

8 (currently amended). The isolated polypeptide according to claim 1, wherein said polypeptide has greater than 99% sequence identity with the polypeptide of SEQ ID NO: 2 or a fragment thereof and has anti-viral activity, antiproliferative activity on cancer cells, the ability to increase levels of TNF- $\alpha$ , IL-2, IL-4, IFN- $\gamma$ , aspartate aminotransferase (ASAT) or alanine aminotransferase (ALAT) *in vivo*, or the ability to induce IFN- $\gamma$  secretion by concanavalin A or phytohemagglutinin stimulated peripheral blood mononuclear cells.

9-50 (canceled).

51 (previously presented). The isolated polypeptide according to claim 1, wherein said polypeptide comprises the amino acid sequence as recited in SEQ ID NO: 2.

52 (previously presented). The isolated polypeptide according to claim 1, wherein said polypeptide consists of the amino acid sequence as recited in SEQ ID NO: 2.

53 (previously presented). The isolated polypeptide according to claim 1, wherein said polypeptide is a fragment of SEQ ID NO: 2 and has anti-viral activity, antiproliferative activity on cancer cells, the ability to increase levels of TNF- $\alpha$ , IL-2, IL-4, IFN- $\gamma$ , aspartate aminotransferase (ASAT) or alanine aminotransferase (ALAT) *in vivo*, or the ability to induce IFN- $\gamma$  secretion by concanavalin A or phytohemagglutinin stimulated peripheral blood mononuclear cells.

54 (currently amended). The isolated polypeptide according to claim 1, wherein said polypeptide is a fragment of a polypeptide having greater than 90%-than 95% sequence identity to SEQ ID NO: 2 and said fragment has anti-viral activity, antiproliferative activity on cancer cells, the ability to increase levels of TNF- $\alpha$ , IL-2, IL-4, IFN- $\gamma$ , aspartate aminotransferase (ASAT) or alanine aminotransferase (ALAT) *in vivo*, or the ability to induce IFN- $\gamma$  secretion by concanavalin A or phytohemagglutinin stimulated peripheral blood mononuclear cells.

55 (currently amended). A composition comprising a pharmaceutical carrier and a polypeptide that:

- (i) comprises or consists of the amino acid sequence as recited in SEQ ID NO:2;
- (ii) is a fragment of SEQ ID NO:2; or
- (iii) has greater than 90%-than 95% sequence identity with the polypeptide of SEQ ID NO: 2 or a fragment thereof;

wherein said isolated polypeptide or fragment has anti-viral activity, antiproliferative activity on cancer cells, the ability to increase levels of TNF- $\alpha$ , IL-2, IL-4, IFN- $\gamma$ , aspartate aminotransferase (ASAT) or alanine aminotransferase (ALAT) *in vivo*, or the ability to induce IFN- $\gamma$  secretion by concanavalin A or phytohemagglutinin stimulated peripheral blood mononuclear cells.

56 (currently amended). The composition according to claim 55, wherein said polypeptide has greater than 95% sequence identity with the polypeptide of SEQ ID NO: 2 or-a fragment thereof and has anti-viral activity, antiproliferative activity on cancer cells, the ability to increase levels of TNF- $\alpha$ , IL-2, IL-4, IFN- $\gamma$ , aspartate aminotransferase (ASAT) or alanine aminotransferase (ALAT) *in vivo*, or the ability to induce IFN- $\gamma$  secretion by concanavalin A or phytohemagglutinin stimulated peripheral blood mononuclear cells.

57 (currently amended). The composition according to claim 55, wherein said polypeptide has greater than 98% sequence identity with the polypeptide of SEQ ID NO: 2 or-a fragment thereof and has anti-viral activity, antiproliferative activity on cancer cells, the ability to increase levels of TNF- $\alpha$ , IL-2, IL-4, IFN- $\gamma$ , aspartate aminotransferase (ASAT) or alanine aminotransferase (ALAT) *in vivo*, or the ability to induce IFN- $\gamma$  secretion by concanavalin A or phytohemagglutinin stimulated pcripheral blood mononuclear cells.

58 (currently amended). The composition according to claim 55, wherein said polypeptide has greater than 99% sequence identity with the polypeptide of SEQ ID NO: 2 or-a fragment thereof and has anti-viral activity, antiproliferative activity on cancer cells, the ability to increase levels of TNF- $\alpha$ , IL-2, IL-4, IFN- $\gamma$ , aspartate aminotransferase (ASAT) or alanine

aminotransferasc (ALAT) *in vivo*, or the ability to induce IFN- $\gamma$  secretion by concanavalin A or phytohemagglutinin stimulated peripheral blood mononuclear cells.

59 (previously presented). The composition according to claim 55, wherein said polypeptide comprises the amino acid sequence as recited in SEQ ID NO: 2.

60 (previously presented). The composition according to claim 55, wherein said polypeptide consists of the amino acid sequence as recited in SEQ ID NO: 2.

61 (previously presented). The composition according to claim 55, wherein said polypeptide is a fragment of SEQ ID NO: 2 and has anti-viral activity, antiproliferative activity on cancer cells, the ability to increase levels of TNF- $\alpha$ , IL-2, IL-4, IFN- $\gamma$ , aspartate aminotransferase (ASAT) or alanine aminotransferase (ALAT) *in vivo*, or the ability to induce IFN- $\gamma$  secretion by concanavalin A or phytohemagglutinin stimulated peripheral blood mononuclear cells.

62 (currently amended). The composition according to claim 55, wherein said polypeptide is a fragment of a polypeptide having greater than 90%than 95% sequence identity to SEQ ID NO: 2 and said fragment has anti-viral activity, antiproliferative activity on cancer cells, the ability to increase levels of TNF- $\alpha$ , IL-2, IL-4, IFN- $\gamma$ , aspartate aminotransferase (ASAT) or alanine aminotransferase (ALAT) *in vivo*, or the ability to induce IFN- $\gamma$  secretion by concanavalin A or phytohemagglutinin stimulated peripheral blood mononuclear cells.